Postdoctoral Scholar in Molecular Engineering, University of Chicago Pritzker School of Molecular Engineering
Dr. Abhimanyu Thakur, PhD, is a biomedical scientist who loves to dig into scientific research questions and invent feasible solutions to broadly pertinent scientific questions with multidisciplinary methods. In particular, he is working to better understand the role of exosomes in diverse aspects of science, including cancer biology, theranostic, and stem cell biology. Exosomes are nanovesicles (30-200 nm) found in extracellular space of various cell types, and in biofluids; having diverse functions including intracellular communication in physiological as well as pathological conditions. Dr. Thakur has expertise in exosome, cancer research, biosensing, drug delivery, neurodegenerative diseases, and biomedical applications of machine learning.
He holds three patents and his research work have been published in top-tier peer-reviewed scientific journals, including Science Advances (IF: 14.14), Nature Communication (IF: 14.92), Protein and Cell (IF: 15.328), Biosensors and Bioelectronics (IF: 12.545), Bioactive Materials (IF: 14.119), Advance Functional Materials (IF: 19.92), Chemical Engineering Journal (IF: 16.744), Journal of Biomedical Sciences (IF: 12.771), CNS Neuroscience & Therapeutics (IF: 7.035), and Brain Behavior Immunity (IF: 19.23).
His honors include prestigious awards or grants including UChicago CORE Grant Award, National Science Foundation Funded I-Corp at Polsky, University of Chicago, a Young Investigator Award by American Association for Cancer Research, Korean Cancer Association, Global Young Scientists Summit Award by Nanyang Technological University, Singapore, the Chow Yei Ching Research Award, and Outstanding Academic Performance Award by the City University of Hong Kong.
Johannesburg in a time of darkness: Ivan Vladislavić’s new memoir reminds us of the city’s fragility
Labour can afford to be far more ambitious with its economic policies – voters are on board
Sudan: civil war stretches into a second year with no end in sight